Short Interest in Prenetics Global Limited (NASDAQ:PRE) Increases By 55.0%

Prenetics Global Limited (NASDAQ:PRE) was the recipient of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 95,934 shares, a growth of 55.0% from the December 15th total of 61,882 shares. Based on an average daily volume of 126,807 shares, the short-interest ratio is currently 0.8 days. Currently, 0.6% of the shares of the stock are short sold. Currently, 0.6% of the shares of the stock are short sold. Based on an average daily volume of 126,807 shares, the short-interest ratio is currently 0.8 days.

Wall Street Analysts Forecast Growth

PRE has been the subject of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a report on Wednesday, October 8th. Wall Street Zen raised Prenetics Global from a “hold” rating to a “buy” rating in a research note on Saturday, November 15th. Finally, Cantor Fitzgerald raised their price target on shares of Prenetics Global from $26.00 to $32.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Prenetics Global has an average rating of “Hold” and a consensus price target of $32.00.

Prenetics Global Trading Up 5.7%

PRE traded up $0.85 on Friday, reaching $15.72. The stock had a trading volume of 216,640 shares, compared to its average volume of 152,237. The company has a market capitalization of $264.57 million, a price-to-earnings ratio of -7.74 and a beta of 0.34. Prenetics Global has a fifty-two week low of $3.09 and a fifty-two week high of $18.48. The firm has a 50-day moving average of $14.99 and a 200-day moving average of $12.02.

Prenetics Global (NASDAQ:PRE) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.14. Prenetics Global had a negative return on equity of 30.12% and a negative net margin of 60.70%.The company had revenue of $23.56 million for the quarter, compared to analysts’ expectations of $26.00 million. Sell-side analysts anticipate that Prenetics Global will post -3.3 EPS for the current fiscal year.

Institutional Trading of Prenetics Global

Several institutional investors have recently modified their holdings of PRE. Stevens Capital Partners acquired a new stake in Prenetics Global in the second quarter valued at $137,000. Aberdeen Group plc bought a new stake in shares of Prenetics Global in the 3rd quarter valued at about $979,000. JPMorgan Chase & Co. bought a new stake in shares of Prenetics Global in the 3rd quarter valued at about $65,000. Finally, UBS Group AG increased its stake in shares of Prenetics Global by 581.9% in the third quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after buying an additional 39,733 shares during the period. Institutional investors own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.